Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...

Hypoglycemia after basal insulin initiation is associated with high clinical and economic burden that precedes insulin initiation and persists during 1 to 2 years of follow-up. Objectives: To assess ...

For patients with type 2 diabetes who are taking multiple daily insulin injections, switching to combination treatment with basal insulin plus an agent from one of two newer glucose-lowering drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Once-weekly insulin efsitora alfa was noninferior to ...

SAN DIEGO – The investigational once-weekly insulin icodec provided superior glucose control compared with the once-daily basal insulins degludec and glargine in type 2 diabetes, results from two new ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...

AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...

A large registry study in young people with type 1 diabetes found that hybrid closed-loop systems were linked to slightly better HbA1c and more time in the target glucose range than open-loop pump ...

Diabetes, affecting millions worldwide, poses a significant challenge to the healthcare system due to the complexity of therapy and difficulty to adequately control the disease. Particularly, patients ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Patients with type 2 diabetes (T2D) who experienced hypoglycemia after adding basal insulin to oral antidiabetes drugs had a significantly greater clinical and economic healthcare burden at baseline, ...